Antiplatelet and Anticoagulation    Intensive Oral Antiplatelet Therapy for Reduction of Ischaemic Events Including Stent Thrombosis in Patients with Acute Coronary Syndromes Treated with Percutaneous Coronary Intervention and Stenting in the Triton-Timi 38 Trial: A Subanalysis of a Randomised Trial Lancet (2008) S. D. Wiviott, et al. Comparison of Angioplasty with Infusion of Tirofiban or Abciximab and with Implantation of Sirolimus-Eluting or Uncoated Stents for Acute Myocardial Infarction: The Multistrategy Randomized Trial JAMA (2008) M. Valgimigli, et al. Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Diabetes Mellitus the Declare-Diabetes Trial (a Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation in Diabetic Patients) J Am Coll Cardiol (2008) 51;1181-7 S. W. Lee, et al. Clopidogrel 600-Mg Double Loading Dose Achieves Stronger Platelet Inhibition Than Conventional Regimens: Results from the Prepair Randomized Study J Am Coll Cardiol (2008) 51;1066-72 P. L. L'Allier, et al. The Relative Safety and Efficacy of Abciximab and Eptifibatide in Patients Undergoing Primary Percutaneous Coronary Intervention: Insights from a Large Regional Registry of Contemporary Percutaneous Coronary Intervention J Am Coll Cardiol (2008) 51;529-35 H. S. Gurm, et al. Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated with Aspirin: The Randomized, Double-Blind Ocla (Omeprazole Clopidogrel Aspirin) Study J Am Coll Cardiol (2008) 51;256-60 M. Gilard, et al. Adjusted Clopidogrel Loading Doses According to Vasodilator-Stimulated Phosphoprotein Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients with Clopidogrel Resistance: A Multicenter Randomized Prospective Study J Am Coll Cardiol (2008) 51;1404-11 L. Bonello, et al. Outcomes with the Use of Glycoprotein Iib/Iiia Inhibitors in Non-St-Segment Elevation Acute Coronary Syndromes Heart (2008) 94;159-65 O. H. Dabbous, et al. Determinants of Thrombin Generation, Fibrinolytic Activity, and Endothelial Dysfunction in Dual-Antiplatelet Therapy: Involvement of Factors Other Than Platelet Aggregability in Virchow's Triad Eur Heart J (2008) Y. Yano, et al. Prasugrel Achieves Greater and Faster P2y12receptor-Mediated Platelet Inhibition Than Clopidogrel Due to More Efficient Generation of Its Active Metabolite in Aspirin-Treated Patients with Coronary Artery Disease Eur Heart J (2008) 29;21-30 L. Wallentin, et al. Prognostic Significance of Post-Clopidogrel Platelet Reactivity Assessed by a Point-of-Care Assay on Thrombotic Events after Drug-Eluting Stent Implantation Eur Heart J (2008) Implantation M. J. Price, et al. The Role of Fondaparinux as an Adjunct to Thrombolytic Therapy in Acute Myocardial Infarction: A Subgroup Analysis of the Oasis-6 Trial Eur Heart J (2008) 29;324-31 R. J. Peters, et al. Effects of Fondaparinux in Patients with St-Segment Elevation Acute Myocardial Infarction Not Receiving Reperfusion Treatment Eur Heart J (2008) 29;315-23 J. Oldgren, et al. One-Year Clinical Outcomes with Abciximab Vs. Placebo in Patients with Non-St-Segment Elevation Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention after Pre-Treatment with Clopidogrel: Results of the Isar-React 2 Randomized Trial Eur Heart J (2008) 29;455-61 G. Ndrepepa, et al. Impact of Anticoagulation Levels on Outcomes in Patients Undergoing Elective Percutaneous Coronary Intervention: Insights from the Steeple Trial Eur Heart J (2008) 29;462-71 . Montalescot, et al. Safety of Percutaneous Coronary Intervention During Uninterrupted Oral Anticoagulant Treatment Eur Heart J (2008) P. P. Karjalainen, et al. Initial Aspirin Dose and Outcome among St-Elevation Myocardial Infarction Patients Treated with Fibrinolytic Therapy Circulation (2008) 117;192-9 J. S. Berger, et al. Optimal Treatment of Renal Artery in-Stent Restenosis: Repeat Stent Placement Versus Angioplasty Alone Catheter Cardiovasc Interv (2008) 71;701-5 Z. M. N'Dandu, et al Effect of Clopidogrel Pretreatment on Angiographic and Clinical Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention for St-Elevation Acute Myocardial Infarction Am J Cardiol (2008) 101;435-9 E. I. Lev, et al. Functional Effects of High Clopidogrel Maintenance Dosing in Patients with Inadequate Platelet Inhibition on Standard Dose Treatment Am J Cardiol (2008) 101;440-5 D. J. Angiolillo, et al. Effects of Clopidogrel and Aspirin in Combination Versus Aspirin Alone on Platelet Activation and Major Receptor Expression in Diabetic Patients: The Plavix Use for Treatment of Diabetes (Pluto-Diabetes) Trial Am Heart J (2008) 155;93 e1-7 V. L. Serebruany, et al. Effects of Pretreatment with Clopidogrel on Nonemergent Percutaneous Coronary Intervention after Fibrinolytic Administration for St-Segment Elevation Myocardial Infarction: A Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (Clarity-Timi) 28 Study Am Heart J (2008) 155;133-9 C. M. Gibson, et al. A Novel Enoxaparin Regime for St Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: A West Sub-Study Catheter Cardiovasc Interv (2007) 70;341-8 R. C. Welsh, et al. Comparison of Speed of Onset of Platelet Inhibition after Loading Doses of Clopidogrel Versus Prasugrel in Healthy Volunteers and Correlation with Responder Status Am J Cardiol (2007) 100;331-6 G. J. Weerakkody, et al. An Analysis of Mortality Rates with Dual-Antiplatelet Therapy in the Primary Prevention Population of the Charisma Trial Eur Heart J (2007) 28;2200-7 T. H. Wang, et al. Prasugrel Achieves Greater and Faster P2y12receptor-Mediated Platelet Inhibition Than Clopidogrel Due to More Efficient Generation of Its Active Metabolite in Aspirin-Treated Patients with Coronary Artery Disease Eur Heart J (2008) 29;21-30 L. Wallentin, et al. Clopidogrel Desensitization after Drug-Eluting Stent Placement J Am Coll Cardiol (2007) 50;2039-43 K. F. von Tiehl, et al. A Double-Blind, Randomized Study on Platelet Aggregation in Patients Treated with a Daily Dose of 150 or 75 Mg of Clopidogrel for 30 Days Eur Heart J (2007) 28;1814-9 N. von Beckerath, et al. The Impact of Advanced Chronic Kidney Disease on in-Hospital Mortality Following Percutaneous Coronary Intervention for Acute Myocardial Infarction Catheter Cardiovasc Interv (2007) 70;701-5 S. Vasu, et al. Cognitive and Cardiac Outcomes 5 Years after Off-Pump Vs on-Pump Coronary Artery Bypass Graft Surgery JAMA (2007) 297;701-8 D. van Dijk, et al. Two-by-Two Factorial Comparison of High-Bolus-Dose Tirofiban Followed by Standard Infusion Versus Abciximab and Sirolimus-Eluting Versus Bare-Metal Stent Implantation in Patients with Acute Myocardial Infarction: Design and Rationale for the Multi-Strategy Trial Am Heart J (2007) 154;39-45 M. Valgimigli, et al. Efficacy and Safety of Triple Antiplatelet Therapy with and without Concomitant Anticoagulation During Elective Percutaneous Coronary Intervention (the Remove Trial) Am J Cardiol (2007) 100;1099-102 R. Valencia, et al. Timing of Glycoprotein Iib/Iiia Inhibitor Use and Outcomes among Patients with Non-St-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention (Results from Crusade) Am J Cardiol (2007) 99;1389-93 P. Tricoci, et al. Patterns of Aspirin Dosing in Non-St-Elevation Acute Coronary Syndromes in the Crusade Quality Improvement Initiative Am J Cardiol (2007) 99;1496-9 S. Tickoo, et al. Effect of Timing of Clopidogrel Administration on 30-Day Clinical Outcomes: 300-Mg Loading Dose Immediately after Coronary Stenting Versus Pretreatment 6 to 24 Hours before Stenting in a Large Unselected Patient Cohort Am Heart J (2007) 153;289-95 T. Szuk, et al. Inhibition of Platelet Aggregation by Azd6140, a Reversible Oral P2y12 Receptor Antagonist, Compared with Clopidogrel in Patients with Acute Coronary Syndromes J Am Coll Cardiol (2007) 50;1852-6 R. F. Storey, et al. Bivalirudin in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis from the Acute Catheterization and Urgent Intervention Triage Strategy (Acuity) Trial Lancet (2007) 369;907-19 G. W. Stone, et al. Antithrombotic Strategies in Patients with Acute Coronary Syndromes Undergoing Early Invasive Management: One-Year Results from the Acuity Trial JAMA (2007) 298;2497-506 G. W. Stone, et al. Routine Upstream Initiation Vs Deferred Selective Use of Glycoprotein Iib/Iiia Inhibitors in Acute Coronary Syndromes: The Acuity Timing Trial JAMA (2007) 297;591-602 G. W. Stone, et al. Global Outcomes of St-Elevation Myocardial Infarction: Comparisons of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis in Myocardial Infarction Study 25 (Extract-Timi 25) Registry and Trial Am Heart J (2007) 154;54-61 B. A. Steinberg, et al. Effectiveness of Glycoprotein Iib/Iiia Inhibitor Use During Primary Coronary Angioplasty: Results of Propensity Analysis Using the New York State Percutaneous Coronary Intervention Reporting System Am J Cardiol (2007) 99;482-5 V. S. Srinivas, et al. The Efficacy and Safety of Combination Glycoprotein Iibiiia Inhibitors and Reduced-Dose Thrombolytic Therapy-Facilitated Percutaneous Coronary Intervention for St-Elevation Myocardial Infarction: A Meta-Analysis of Randomized Clinical Trials Am Heart J (2007) 153;579-86 M. C. Sinno, et al. Effects of Clopidogrel and Aspirin in Combination Versus Aspirin Alone on Platelet Activation and Major Receptor Expression in Diabetic Patients: The Plavix Use for Treatment of Diabetes (Pluto-Diabetes) Trial Am Heart J (2008) 155;93 e1-7 V. L. Serebruany, et al. Consistent Platelet Inhibition During Long-Term Maintenance-Dose Clopidogrel Therapy among 359 Compliant Outpatients with Documented Vascular Disease Am Heart J (2007) 153;371-7 V. L. Serebruany, et al. A Strategy of Using Enoxaparin as Adjunctive Antithrombin Therapy Reduces Death and Recurrent Myocardial Infarction in Patients Who Achieve Early St-Segment Resolution after Fibrinolytic Therapy: The Extract-Timi 25 Ecg Study Eur Heart J (2007) 28;2070-6 B. M. Scirica, et al. Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in Patients with St-Segment Elevation Myocardial Infarction Also Treated with Clopidogrel J Am Coll Cardiol (2007) 49;2256-63 M. S. Sabatine, et al. Early Abciximab Administration before Primary Percutaneous Coronary Intervention Improves Infarct-Related Artery Patency and Left Ventricular Function in High-Risk Patients with Anterior Wall Myocardial Infarction: A Randomized Study Am Heart J (2007) 153;360-5 T. Rakowski, et al. Effects of Fondaparinux in Patients with St-Segment Elevation Acute Myocardial Infarction Not Receiving Reperfusion Treatment Eur Heart J (2007) J. Oldgren, et al. Combining Warfarin and Antiplatelet Therapy after Coronary Stenting in the Global Registry of Acute Coronary Events: Is It Safe and Effective to Use Just One Antiplatelet Agent? Eur Heart J (2007) 28;1717-22 M. C. Nguyen, et al. Efficacy and Safety of the Low-Molecular Weight Heparin Enoxaparin Compared with Unfractionated Heparin across the Acute Coronary Syndrome Spectrum: A Meta-Analysis Eur Heart J (2007) 28;2077-86 S. A. Murphy, et al. Effect of Enoxaparin Versus Unfractionated Heparin in Diabetic Patients with St-Elevation Myocardial Infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis in Myocardial Infarction Study 25 (Extract-Timi 25) Trial Am Heart J (2007) 154;1078-84, 1084 e1 D. A. Morrow, et al. Abciximab in Primary Coronary Stenting of St-Elevation Myocardial Infarction: A European Meta-Analysis on Individual Patients' Data with Long-Term Follow-Up Eur Heart J (2007) 28;443-9 G. Montalescot, et al. Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Results from the Oasis-5 Trial J Am Coll Cardiol (2007) 50;1742-51 S. R. Mehta, et al. Sex and Effect of Abciximab in Patients with Acute Coronary Syndromes Treated with Percutaneous Coronary Interventions: Results from Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 Trial Am Heart J (2007) 154;158 e1-7 J. Mehilli, et al. Outcomes and Optimal Antithrombotic Therapy in Women Undergoing Fibrinolysis for St-Elevation Myocardial Infarction Circulation (2007) 115;2822-8 J. L. Mega, et al. Optimal Platelet Inhibition in Patients Undergoing Pci: Data from the Multicenter Registry of High-Risk Percutaneous Coronary Intervention and Adequate Platelet Inhibition (Mr Pci) Study Am Heart J (2007) 154;344 e1-5 H. M. Mardikar, et al. Randomized Early Versus Late Abciximab in Acute Myocardial Infarction Treated with Primary Coronary Intervention (Relax-Ami Trial) J Am Coll Cardiol (2007) 49;1517-24 M. Maioli, et al. Comparison of Triple Versus Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation (from the Declare-Long Trial) Am J Cardiol (2007) 100;1103-8 S. W. Lee, et al. Effects of Triple Antiplatelet Therapy (Aspirin, Clopidogrel, and Cilostazol) on Platelet Aggregation and P-Selectin Expression in Patients Undergoing Coronary Artery Stent Implantation Am J Cardiol (2007) 100;610-4 B. K. Lee, et al. Endogenous Testosterone and Mortality Due to All Causes, Cardiovascular Disease, and Cancer in Men: European Prospective Investigation into Cancer in Norfolk (Epic-Norfolk) Prospective Population Study Circulation (2007) 116;2694-701 K. T. Khaw, et al. Safety and Efficacy of Combined Antiplatelet-Warfarin Therapy after Coronary Stenting Eur Heart J (2007) 28;726-32 P. P. Karjalainen, et al. Comparison of Effectiveness of Enoxaparin Versus Unfractionated Heparin to Reduce Silent and Clinically Apparent Acute Myocardial Infarction in Patients Presenting with Non-St-Segment Elevation Acute Coronary Syndrome Am J Cardiol (2007) 99;186-8 S. Jolly, et al. Clopidogrel and Long-Term Outcomes after Stent Implantation for Acute Coronary Syndrome Am Heart J (2007) 154;846-51 P. M. Ho, et al. Effects of Platelet Glycoprotein Iib/Iiia Receptor Blockers in Non-St Segment Elevation Acute Coronary Syndromes: Benefit and Harm in Different Age Subgroups Heart (2007) 93;450-5 A. V. Hernandez, et al. Immediate and Intermediate Results of Intracoronary Stand-Alone Bolus Administration of Eptifibatide During Coronary Intervention (Ice) Study Am Heart J (2007) 154;345-51 W. Hassan, et al. Usefulness of Routine Unfractionated Heparin Infusion Following Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction in Patients Not Receiving Glycoprotein Iib/Iiia Inhibitors Am J Cardiol (2007) 99;202-7 K. J. Harjai, et al. Evaluation of Dose-Related Effects of Aspirin on Platelet Function: Results from the Aspirin-Induced Platelet Effect (Aspect) Study Circulation (2007) 115;3156-64 P. A. Gurbel, et al. Preliminary Experience with Intravenous P2y12 Platelet Receptor Inhibition as an Adjunct to Reduced-Dose Alteplase During Acute Myocardial Infarction: Results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (Step-Ami) Angiographic Trial Am Heart J (2007) 154;702-9 A. B. Greenbaum, et al. Recombinant Nematode Anticoagulant Protein C2 in Patients with Non-St-Segment Elevation Acute Coronary Syndrome: The Anthem-Timi-32 Trial J Am Coll Cardiol (2007) 49;2398-407 R. P. Giugliano, et al. Enoxaparin Is Superior to Unfractionated Heparin in Patients with St Elevation Myocardial Infarction Undergoing Fibrinolysis Regardless of the Choice of Lytic: An Extract-Timi 25 Analysis Eur Heart J (2007) 28;1566-73 R. R. Giraldez, et al. First-in-Human Evaluation of Anti Von Willebrand Factor Therapeutic Aptamer Arc1779 in Healthy Volunteers Circulation (2007) 116;2678-86 J. C. Gilbert, et al. Effects of Pretreatment with Clopidogrel on Nonemergent Percutaneous Coronary Intervention after Fibrinolytic Administration for St-Segment Elevation Myocardial Infarction: A Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (Clarity-Timi) 28 Study Am Heart J (2008) 155;133-9 C. M. Gibson, et al. Percutaneous Coronary Intervention in Patients Receiving Enoxaparin or Unfractionated Heparin after Fibrinolytic Therapy for St-Segment Elevation Myocardial Infarction in the Extract-Timi 25 Trial J Am Coll Cardiol (2007) 49;2238-46 C. M. Gibson, et al. Residual Platelet Activity Is Increased in Clopidogrel- and Asa-Treated Patients with Coronary Stenting for Acute Coronary Syndromes Compared with Stable Coronary Artery Disease Heart (2007) T. Geisler, et al. The Impact of Renal Dysfunction on Outcomes in the Extract-Timi 25 Trial J Am Coll Cardiol (2007) 49;2249-55 K. A. Fox, et al. The Impact of Oral Antiplatelet Responsiveness on the Long-Term Prognosis after Coronary Stenting Am Heart J (2007) 154;676-81 S. G. Foussas, et al. Impact of Bivalirudin on Outcomes after Percutaneous Coronary Revascularization with Drug-Eluting Stents Am Heart J (2007) 154;695-701 D. N. Feldman, et al. Heritability of Platelet Responsiveness to Aspirin in Activation Pathways Directly and Indirectly Related to Cyclooxygenase-1 Circulation (2007) 115;2490-6 N. Faraday, et al. Clopidogrel Use and Long-Term Clinical Outcomes after Drug-Eluting Stent Implantation JAMA (2007) 297;159-68 E. L. Eisenstein, et al. Transfer with Gp Iib/Iiia Inhibitor Tirofiban for Primary Percutaneous Coronary Intervention Vs. On-Site Thrombolysis in Patients with St-Elevation Myocardial Infarction (Stemi): A Randomized Open-Label Study for Patients Admitted to Community Hospitals Eur Heart J (2007) 28;2438-48 S. Dobrzycki, et al. Antiplatelet Therapy and Progression of Coronary Artery Disease: A Placebo-Controlled Trial with Angiographic and Clinical Follow-up after Myocardial Infarction Am Heart J (2007) 153;66 e1-8 H. J. Dieker, et al. Complementary Effects of Thienopyridine Pretreatment and Platelet Glycoprotein Iib/Iiia Integrin Blockade with Eptifibatide in Coronary Stent Intervention; Results from the Esprit Trial Catheter Cardiovasc Interv (2007) 70;43-50 J. P. Dery, et al. Effectiveness and Safety of Reduced-Dose Enoxaparin in Non-St-Segment Elevation Acute Coronary Syndrome Followed by Antiplatelet Therapy Alone for Percutaneous Coronary Intervention Am J Cardiol (2007) 100;1376-82 S. J. Denardo, et al. Adjunctive Benefits from Low-Molecular-Weight Heparins as Compared to Unfractionated Heparin among Patients with St-Segment Elevation Myocardial Infarction Treated with Thrombolysis. A Meta-Analysis of the Randomized Trials Am Heart J (2007) 154;1085 e1-6 G. De Luca and P. Marino Macroscopic Thrombus Formation on Angioplasty Equipment Following Antithrombin Therapy with Enoxaparin Catheter Cardiovasc Interv (2007) 70;847-53 A. Dana, et al. Outcomes with the Use of Glycoprotein Iib/Iiia Inhibitors in Non-St-Segment Elevation Acute Coronary Syndromes Heart (2008) 94;159-65 O. H. Dabbous, et al. Safety, Tolerability, and Initial Efficacy of Azd6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared with Clopidogrel, in Patients with Non-St-Segment Elevation Acute Coronary Syndrome: Primary Results of the Disperse-2 Trial J Am Coll Cardiol (2007) 50;1844-51 C. P. Cannon, et al. Poor Responsiveness to Clopidogrel: Drug-Specific or Class-Effect Mechanism? Evidence from a Clopidogrel-to-Ticlopidine Crossover Study J Am Coll Cardiol (2007) 50;1132-7 G. Campo, et al. Impact of Platelet Reactivity after Clopidogrel Administration on Drug-Eluting Stent Thrombosis J Am Coll Cardiol (2007) 49;2312-7 P. Buonamici, et al. The Impact of Obesity on Mortality in Ua/Non-St-Segment Elevation Myocardial Infarction Eur Heart J (2007) 28;1694-701 H. J. Buettner, et al. Measuring Aspirin Resistance, Clopidogrel Responsiveness, and Postprocedural Markers of Myonecrosis in Patients Undergoing Percutaneous Coronary Intervention Am J Cardiol (2007) 99;1518-22 A. N. Buch, et al. Interactions between Heparins, Glycoprotein Iib/Iiia Antagonists, and Coronary Intervention. The Global Registry of Acute Coronary Events (Grace) Am Heart J (2007) 153;960-9 D. Brieger, et al. A Comparison of Prasugrel and Clopidogrel Loading Doses on Platelet Function: Magnitude of Platelet Inhibition Is Related to Active Metabolite Formation Am Heart J (2007) 153;66 e9-16 J. T. Brandt, et al. Increased Risk in Patients with High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing Percutaneous Coronary Intervention: Is the Current Antiplatelet Therapy Adequate? J Am Coll Cardiol (2007) 49;657-66 K. P. Bliden, et al. Patients with Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the Charisma Trial J Am Coll Cardiol (2007) 49;1982-8 D. L. Bhatt, et al. Long-Term Versus Short-Term Clopidogrel Therapy in Patients Undergoing Coronary Stenting (from the Randomized Argentine Clopidogrel Stent [Racs] Trial) Am J Cardiol (2007) 99;349-52 V. Bernardi, et al. Initial Aspirin Dose and Outcome among St-Elevation Myocardial Infarction Patients Treated with Fibrinolytic Therapy Circulation (2008) 117;192-9 J. S. Berger, et al. Comparison of Two Antiplatelet Regimens (Aspirin Alone Versus Aspirin + Ticlopidine or Clopidogrel) after Intracoronary Implantation of a Carbofilm-Coated Stent Am J Cardiol (2007) 99;1062-6 A. L. Bartorelli, et al. Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients with Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (Optimus) Study Circulation (2007) 115;708-16 D. J. Angiolillo, et al. Oral Anticoagulant and Antiplatelet Therapy and Peripheral Arterial Disease N Engl J Med (2007) 357;217-27 S. Anand, et al. Incidence and Predictors of Drug-Eluting Stent Thrombosis During and after Discontinuation of Thienopyridine Treatment Circulation (2007) 116;745-54 F. Airoldi, et al.